Congo to receive 70,000 doses of Ervebo Ebola vaccine which has been effective in past outbreaks
By Adele Rutherford ·
When Tedros Adhanom Ghebreyesus calls the allocation of resources “an important example of global solidarity in action,” I confess, my first thought is not one of gratitude, but…
The Spectacle of Global Solidarity vs. Procedural Due Process
When Tedros Adhanom Ghebreyesus calls the allocation of resources “an important example of global solidarity in action,” I confess, my first thought is not one of gratitude, but of procedural skepticism. We have become so accustomed to the spectacle of scientific progress being moved—a vaccine allocated from a stockpile—that we forget to scrutinize whether those resources are actually fit for purpose. The latest story from eastern Congo regarding 70,000 doses of Ervebo is a textbook case of impressive logistics masking fundamental scientific uncertainty.
When the Strain Outpaces the Science
The record, as reported by Euronews and SABC News, is clear: the Democratic Republic of Congo is receiving 70,000 doses. This allocation includes 20,000 doses for a Phase 3 clinical trial to assess effectiveness against the Bundibugyo virus, while the remaining 50,000 shots are earmarked for frontline and health workers. Herein lies the critical distinction that deserves far more attention than any celebratory press release: Ervebo is approved for Zaire ebolavirus, not the specific Bundibugyo strain driving this current epidemic. While WHO stated that “early laboratory and animal data suggest it may provide some protection,” I see a reliance on preliminary findings to justify a massive deployment. The process has jumped ahead of the evidence.
Lessons from the Spanish Flu Pandemic
This situation, with its rapid spread across six provinces and its staggering case fatality rate of 47.5%, is not unprecedented in its brutality. It reminds me sharply of the 1918–1920 flu pandemic—the one history has named the Spanish Flu. That was a global biological crisis that required more than just the deployment of scientific resources; it demanded an understanding of viral mechanics, transmission vectors, and immunity—the process of disease control. The sheer scale of death from this current outbreak, surpassing even the 2018-2020 figures, is a testament to how quickly a biological threat can overwhelm systems when the protective measure is based on assumption rather than established fact.
The global community has conflated availability with efficacy. They are treating the provision of doses as if it were the solution itself. But history teaches us that simply having the vaccine—or even the most promising candidate, like those for Bundibugyo currently in development by Moderna and Oxford—does not guarantee containment. It requires a rigorous understanding of how the virus has mutated and how the human body will respond to the specific strain at hand.
The true failure here is not one of funding or logistics; it is a failure of intellectual humility. The international community, much like so many institutions that mistake procedure for principle, continues to prioritize the appearance of action over the slow, painstaking work of validation. Until the scientific process can definitively prove its mechanism against the Bundibugyo virus in human subjects—not just animals—these 70,000 doses remain a potent symbol of well-intentioned guesswork.
Sources
- Euronews: DR Congo to receive 70,000 doses of Ebola vaccine used in past outbreaks, WHO says
- Anadolu Agency: DR Congo to get 70,000 Ebola vaccines to contain outbreak
- SABC News: DRC to receive 70 000 Ervebo vaccines to contain Ebola outbreak: WHO
- franceinfo: Face à l'épidémie d'Ebola, l'Organisation mondiale de la santé fournit 70 000 doses de vaccin Ervebo à la RDC